The gut microbiome has emerged as a crucial player in modulating cancer therapies, including radiotherapy. In the case of breast cancer, the interplay between the microbiome and radiotherapy-derived metabolites may enhance therapeutic outcomes and minimize adverse effects. In this review, we explore the bidirectional relationship between the gut microbiome and breast cancer. We explain how gut microbiome composition influences cancer progression and treatment response, and how breast cancer and its treatments influence microbiome composition. A dual role for radiotherapy-derived metabolites is explored in this article, highlighting both their therapeutic benefits and potential hazards. By integrating genomics, metabolomics, and bioinformatics tools, we present a comprehensive overview of these interactions. The study provides real-world insight through case studies and clinical trials, while therapeutic innovations such as probiotics, and dietary interventions are examined for their potential to modulate the microbiome and enhance treatment effectiveness. Moreover, ethical considerations and patient perspectives are discussed, ensuring a comprehensive understanding of the subject. Towards revolutionizing treatment strategies and improving patient outcomes, the review concludes with future research directions. It also envisions integrating microbiome and metabolite research into personalized breast cancer therapy.
肠道微生物组已成为调节癌症治疗（包括放射治疗）的关键因素。在乳腺癌治疗中，微生物组与放射治疗衍生代谢物之间的相互作用可能提升治疗效果并减少不良反应。本综述探讨了肠道微生物组与乳腺癌之间的双向关系：一方面阐释肠道微生物组成如何影响癌症进展和治疗反应，另一方面分析乳腺癌及其治疗如何影响微生物组构成。文章重点探讨了放射治疗衍生代谢物的双重作用，既揭示其治疗效益，也警示其潜在风险。通过整合基因组学、代谢组学和生物信息学工具，我们对这些相互作用进行了全面综述。研究通过案例分析和临床试验提供了现实视角，同时探讨了益生菌和饮食干预等治疗创新手段在调节微生物组、提升治疗效果方面的潜力。此外，文章还讨论了伦理考量与患者视角，确保对该主题形成全面理解。为推进治疗策略革新和改善患者预后，本文最后提出了未来研究方向，并展望了将微生物组与代谢物研究整合到个性化乳腺癌治疗中的前景。
The Role of the Microbiome and of Radiotherapy-Derived Metabolites in Breast Cancer
肿瘤(癌症)患者之家